Insider Transactions in Q1 2025 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
46,409
-1.78%
|
$46,409
$1.83 P/Share
|
|
Mar 03
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,144
-0.88%
|
$7,144
$1.83 P/Share
|
|
Feb 03
2025
|
Nicholas Grund Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
55,621
-11.16%
|
$111,242
$2.1 P/Share
|
|
Feb 03
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
30,202
-9.73%
|
$60,404
$2.1 P/Share
|
|
Feb 03
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,506
-2.96%
|
$101,012
$2.1 P/Share
|
|
Feb 03
2025
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
144,250
-2.65%
|
$288,500
$2.1 P/Share
|
|
Jan 31
2025
|
Nicholas Grund Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+28.12%
|
-
|
|
Jan 31
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+21.49%
|
-
|
|
Jan 31
2025
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+18.36%
|
-
|
|
Jan 31
2025
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
701,000
+20.32%
|
-
|
|
Jan 31
2025
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
194,900
+26.35%
|
-
|
|
Jan 17
2025
|
Ron Frieson |
BUY
Exercise of conversion of derivative security
|
Direct |
20,100
+17.65%
|
$0
$0.45 P/Share
|